Odyssey Therapeutics Inc. has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small-molecule medicines against select therapeutic targets.

A group of scientists at Shanghai Virogin Biotech Co. and Zhujiang Hospital in China designed a new mRNA vaccine that could prevent tumor formation associated with human papillomavirus 16 (HPV16) and also reduce its size if used as a treatment.

Altamira Therapeutics Ltd. has entered into a collaboration agreement with Univercells SA to evaluate the use of the company’s proprietary Semaphore platform for the delivery of mRNA vaccines.

Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with the University of Oxford to verify drug discovery seeds and obtain screening compounds for the creation of new medicines.

Deep learning algorithms have enabled the discovery of molecular structures of interest in biomedicine to design treatments against aggressive diseases such as idiopathic pulmonary fibrosis (IPF). Scientists at Insilico Medicine Inc. selected a target for IPF using artificial intelligence (AI), then designed an inhibitor to block it, and tested it in vitro, in vivo, and in clinical trials.

Samsung Life Science Fund, created jointly between Samsung Biologics Co. Ltd., Samsung Bioepis Co. Ltd. and Samsung C&T, and managed by Samsung Venture Investment Corp., and Brickbio Inc. have announced Samsung’s investment in preclinical-stage biopharmaceutical company Brickbio.

The University of California, Berkeley has announced the launch of the UC Berkeley Molecular Therapeutics Initiative (MTI) designed to accelerate drug discovery. The aim is to bridge fundamental research in rare neurological and metabolic diseases with drug discovery to identify and accelerate novel therapeutic modalities into the clinic.

One topic at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held in Denver this month was that resistance to antiretroviral therapy (ART) has become a public health problem for people living with HIV. Without a vaccine or a cure, these patients depend on treatments that suppress viremia by preventing the virus from replicating. They are lifelong treatments and, until new advances succeed in eradicating the virus from reservoirs, the only option available.

Transcode Therapeutics Inc. has reported promising proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics AG.